Alumis Inc.
ALMS
Rank in Stocks
#9439
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Share Price
$6.55
Last synced: 2026-11-09
Market Cap
$847.80M
Change (1 day)
8.62%
Change (1 year)
23.58%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Alumis Inc. (ALMS)
Category
Healthcare
Operating Margin for Alumis Inc. (ALMS)
Operating Margin as of November 2026 TTM: -6,204.39%
According to Alumis Inc.'s latest financial reports, its current operating margin (TTM) is -6,204.39%. At the end of 2025 the company had an operating margin of -1,776.32%.
Operating Margin history for Alumis Inc. from 2022 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -6,204.39% | 249.28% |
| 2025 | -1,776.32% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.98% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Alumis Inc.'s operating margin
What is Alumis Inc.'s operating margin?
Alumis Inc.'s operating margin is -6,204.39%, as of Nov 2026.
What was Alumis Inc.'s operating margin in 2025?
In 2025, Alumis Inc.'s operating margin was -1,776.32%, compared with 0.00% in 2024.
How has Alumis Inc.'s operating margin changed since 2022?
From 2022 to 2025, Alumis Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2025 (-1,776.32%).
How does Alumis Inc.'s operating margin compare with similar companies?
Alumis Inc.'s operating margin (-6,204.39%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.